Week in Review: Amgen to Build China Presence with Partnerships/M&A

Amgen is planning to increase its participation in the China market, using a combination of partnerships and M&A to build a presence; China Shenghuo Pharma received a proposal from its majority owner to take the company private at a price of $.15 per share; Zhejiang Shanshi Medical Device acquired the China distribution rights to Tensys Medical’s hemodynamic patient monitoring systems; OxOnc Development, a US oncology company, will conduct a Phase III trial of a Pfizer cancer drug in China and other East Asian countries; and Celgene Corp. of the US was granted China approval for Revlimid ® (lenalidomide) to treat multiple myeloma. More details…. Stock Symbols: (NSDQ: AMGN) (Pinksheets: CKUN) (NYSE: PFE) (NSDQ: CELG) Share this with colleagues: // //